A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Eric S SchaferRachel E RauStacey BergXiaowei LiuCharles G MinardDavid D'AdamoRachael ScottLarisa ReydermanGresel MartinezSandhya DevarajanJoel M ReidElizabeth FoxBrenda J WeigelSusan M BlaneyPublished in: Pediatric blood & cancer (2018)
Eribulin was well tolerated in children with refractory or recurrent solid tumors with neutropenia identified as the primary DLT. The RP2D of eribulin is 1.4 mg/m2 /dose on days 1 and 8 of a 21-day cycle.